This highlights the importance of detecting subtle changes in brain structure and function to identify early stages of the disease [3]. However, the diagnosis of AD has not been standardized, and the primary diagnostic methods include magnetic resonance imaging (MRI) and positron emission tomography (PET) brain imaging, biochemical analysis of Aβ42/40, and total tau (t-tau) and phosphorylated tau (p-tau181) levels in the CSF [5]. Here, MAPT is linked to Alzheimer disease.